Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
| The Manila Times
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ('Tenax” or 'Tenax Therapeutics” or the 'Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles.